GMP-based CD133 + cells isolation maintains progenitor angiogenic properties and enhances standardization in cardiovascular cell therapy

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 6 B, 2010, Pages 1619-1634

  Gaipa, Giuseppe ^a,b   Tilenni, Manuela ^c   Straino, Stefania ^d   Burba, Ilaria ^c   Zaccagnini, Germana ^d   Belotti, Daniela ^a   Biagi, Ettore ^a   Valentini, Marco ^e   Perseghin, Paolo ^a   Parma, Matteo ^a   Campli, Cristiana Di ^e   Biondi, Andrea ^b   Capogrossi, Maurizio C ^d   Pompilio, Giulio ^c   Pesce, Maurizio ^c  

^a SAN GERARDO HOSPITAL   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c CENTRO CARDIOLOGICO MONZINO   (Italy)

^d LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^e BioRep srl   (Italy)

Author keywords

Angiogenesis; CD133; Cell therapy; GMP; Ischemia; Validation

Indexed keywords

CD133 ANTIGEN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL; ARTICLE; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SEPARATION; CELL SURVIVAL; CYTOLOGY; FETUS BLOOD; HEART MUSCLE ISCHEMIA; HINDLIMB; HUMAN; METABOLISM; METHODOLOGY; MOUSE; PATHOLOGY; PHENOTYPE; QUALITY CONTROL; STANDARD; STEM CELL; STEM CELL TRANSPLANTATION; VASCULARIZATION;

ANIMALS; ANTIGENS, CD; CARDIOVASCULAR DISEASES; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SEPARATION; CELL SURVIVAL; FETAL BLOOD; GLYCOPROTEINS; HINDLIMB; HUMANS; MICE; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDES; PHENOTYPE; QUALITY CONTROL; REFERENCE STANDARDS; STEM CELL TRANSPLANTATION; STEM CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 77955153717     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00854.x     Document Type: Article

References (61)

1. Segers VF, Lee RT. Stem-cell therapy for cardiac disease. Nature. 2008, 451:937-42.
2. Passier R, van Laake LW, Mummery CL. Stem-cell-based therapy and lessons from the heart. Nature. 2008, 453:322-9.
3. Kajiguchi M, Kondo T, Izawa H. Safety and efficacy of autologous progenitor cell transplantation for therapeutic angiogenesis in patients with critical limb ischemia. Circ J. 2007, 71:196-201.
4. Kang S, Yang YJ, Li CJ. Effects of intracoronary autologous bone marrow cells on left ventricular function in acute myocardial infarction: a systematic review and meta-analysis for randomized controlled trials. Coron Artery Dis. 2008, 19:327-35.
5. Abdel-Latif A, Bolli R, Tleyjeh IM. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med. 2007, 167:989-97.
6. Martin-Rendon E, Brunskill SJ, Hyde CJ. Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. Eur Heart J. 2008, 29:1807-18.
7. Martin-Rendon E, Brunskill S, Doree C. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev. 2008, CD006536.
8. Kawamoto A, Iwasaki H, Kusano K. CD34-positive cells exhibit increased potency and safety for therapeutic neovascularization after myocardial infarction compared with total mononuclear cells. Circulation. 2006, 114:2163-9.
9. Epstein SE, Stabile E, Kinnaird T. Janus phenomenon: the interrelated tradeoffs inherent in therapies designed to enhance collateral formation and those designed to inhibit atherogenesis. Circulation. 2004, 109:2826-31.
10. van der Bogt KE, Sheikh AY, Schrepfer S. Comparison of different adult stem cell types for treatment of myocardial ischemia. Circulation. 2008, 118:S121-9.
11. Sekiguchi H, Ii M, Losordo DW. The relative potency and safety of endothelial progenitor cells and unselected mononuclear cells for recovery from myocardial infarction and ischemia. J Cell Physiol. 2009, 219:235-42.
12. Liew A, Barry F, O'Brien T. Endothelial progenitor cells: diagnostic and therapeutic considerations. Bioessays. 2006, 28:261-70.
13. Ingram DA, Caplice NM, Yoder MC. Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells. Blood. 2005, 106:1525-31.
14. Ingram DA, Mead LE, Tanaka H. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood. 2004, 104:2752-60.
15. Prater DN, Case J, Ingram DA. Working hypothesis to redefine endothelial progenitor cells. Leukemia. 2007, 21:1141-9.
16. Hur J, Yoon CH, Kim HS. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol. 2004, 24:288-93.
17. Timmermans F, Van Hauwermeiren F, De Smedt M. Endothelial outgrowth cells are not derived from CD133+ cells or CD45+ hematopoietic precursors. Arterioscler Thromb Vasc Biol. 2007, 27:1572-9.
18. Sieveking DP, Buckle A, Celermajer DS. Strikingly different angiogenic properties of endothelial progenitor cell subpopulations: insights from a novel human angiogenesis assay. J Am Coll Cardiol. 2008, 51:660-8.
19. Zhang Y, Ingram DA, Murphy MP. Release of proinflammatory mediators and expression of proinflammatory adhesion molecules by endothelial progenitor cells. Am J Physiol Heart Circ Physiol 2009, 296:H1675-82.
20. Timmermans F, Plum J, Yoder MC. Endothelial progenitor cells: identity defined? J Cell Mol Med. 2008, 13:87-102.
21. Ma N, Ladilov Y, Moebius JM. Intramyocardial delivery of human CD133+ cells in a SCID mouse cryoinjury model: bone marrow vs. cord blood-derived cells. Cardiovasc Res. 2006, 71:158-69.
22. Agbulut O, Vandervelde S, Al Attar N. Comparison of human skeletal myoblasts and bone marrow-derived CD133+ progenitors for the repair of infarcted myocardium. J Am Coll Cardiol. 2004, 44:458-63.
23. Botta R, Gao E, Stassi G. Heart infarct in NOD-SCID mice: therapeutic vasculogenesis by transplantation of human CD34+ cells and low dose CD34+KDR+ cells. FASEB J. 2004, 18:1392-4.
24. Leor J, Guetta E, Feinberg MS. Human umbilical cord blood-derived CD133+ cells enhance function and repair of the infarcted myocardium. Stem Cells. 2006, 24:772-80.
25. Yeh ET, Zhang S, Wu HD. Transdifferentiation of human peripheral blood CD34+-enriched cell population into cardiomyocytes, endothelial cells, and smooth muscle cells in vivo. Circulation. 2003, 108:2070-3.
26. Schatteman GC, Hanlon HD, Jiao C. Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice. J Clin Invest. 2000, 106:571-8.
27. Awad O, Dedkov EI, Jiao C. Differential healing activities of CD34+ and CD14+ endothelial cell progenitors. Arterioscler Thromb Vasc Biol. 2006, 26:758-64.
28. Madeddu P, Emanueli C, Pelosi E. Transplantation of low dose CD34+KDR+ cells promotes vascular and muscular regeneration in ischemic limbs. FASEB J. 2004, 18:1737-9.
29. Pesce M, Orlandi A, Iachininoto MG. Myoendothelial differentiation of human umbilical cord blood-derived stem cells in ischemic limb tissues. Circ Res. 2003, 93:e51-62.
30. Sivan-Loukianova E, Awad OA, Stepanovic V. CD34+ blood cells accelerate vascularization and healing of diabetic mouse skin wounds. J Vasc Res. 2003, 40:368-77.
31. Iwasaki H, Kawamoto A, Ishikawa M. Dose-dependent contribution of CD34-positive cell transplantation to concurrent vasculogenesis and cardiomyogenesis for functional regenerative recovery after myocardial infarction. Circulation. 2006, 113:1311-25.
32. Goussetis E, Manginas A, Koutelou M. Intracoronary infusion of CD133+ and CD133-CD34+ selected autologous bone marrow progenitor cells in patients with chronic ischemic cardiomyopathy: cell isolation, adherence to the infarcted area, and body distribution. Stem Cells. 2006, 24:2279-83.
33. Schots R, De Keulenaer G, Schoors D. Evidence that intracoronary-injected CD133+ peripheral blood progenitor cells home to the myocardium in chronic postinfarction heart failure. Exp Hematol. 2007, 35:1884-90.
34. Hofmann M, Wollert KC, Meyer GP. Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation. 2005, 111:2198-202.
35. Bartunek J, Vanderheyden M, Vandekerckhove B. Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: feasibility and safety. Circulation. 2005, 112:I178-83.
36. Boyle AJ, Whitbourn R, Schlicht S. Intra-coronary high-dose CD34+ stem cells in patients with chronic ischemic heart disease: a 12-month follow-up. Int J Cardiol. 2006, 109:21-7.
37. Losordo DW, Schatz RA, White CJ. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation. 2007, 115:3165-72.
38. Pompilio G, Steinhoff G, Liebold A. Direct minimally invasive intramyocardial injection of bone marrow-derived AC133+ stem cells in patients with refractory ischemia: preliminary results. Thorac Cardiovasc Surg. 2008, 56:71-6.
39. Stamm C, Westphal B, Kleine HD. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet. 2003, 361:45-6.
40. Stamm C, Kleine HD, Choi YH. Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies. J Thorac Cardiovasc Surg. 2007, 133:717-25.
41. Seeger FH, Zeiher AM, Dimmeler S. Cell-enhancement strategies for the treatment of ischemic heart disease. Nat Clin Pract Cardiovasc Med 2007, 4:S110-3.
42. Hill JM, Zalos G, Halcox JP. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003, 348:593-600.
43. Couffinhal T, Silver M, Zheng LP. Mouse model of angiogenesis. Am J Pathol. 1998, 152:1667-79.
44. Emanueli C, Salis MB, Pinna A. Nerve growth factor promotes angiogenesis and arteriogenesis in ischemic hindlimbs. Circulation. 2002, 106:2257-62.
45. Zaccagnini G, Martelli F, Fasanaro P. p66ShcA modulates tissue response to hindlimb ischemia. Circulation. 2004, 109:2917-23.
46. Perseghin P, Gaipa G, Dassi M. CD34+ stem cell recovery after positive selection of " overloaded" immunomagnetic columns. Stem Cells Dev. 2005, 14:740-3.
47. Gaipa G, Dassi M, Perseghin P. Allogeneic bone marrow stem cell transplantation following CD34+ immunomagnetic enrichment in patients with inherited metabolic storage diseases. Bone Marrow Transplant. 2003, 31:857-60.
48. Asahara T, Murohara T, Sullivan A. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997, 275:964-7.
49. Seeger FH, Tonn T, Krzossok N. Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur Heart J. 2007, 28:766-72.
50. Kawamoto A, Losordo DW. Endothelial progenitor cells for cardiovascular regeneration. Trends Cardiovasc Med. 2008, 18:33-7.
51. Lipinski MJ, Biondi-Zoccai GG, Abbate A. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials. J Am Coll Cardiol. 2007, 50:1761-7.
52. Dimmeler S, Aicher A, Vasa M. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest. 2001, 108:391-7.
53. Zemani F, Silvestre JS, Fauvel-Lafeve F. Ex vivo priming of endothelial progenitor cells with SDF-1 before transplantation could increase their proangiogenic potential. Arterioscler Thromb Vasc Biol. 2008, 28:644-50.
54. Carmona G, Chavakis E, Koehl U. Activation of Epac stimulates integrin-dependent homing of progenitor cells. Blood. 2008, 111:2640-6.
55. Yoon CH, Hur J, Park KW. Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases. Circulation. 2005, 112:1618-27.
56. Chavakis E, Urbich C, Dimmeler S. Homing and engraftment of progenitor cells: a prerequisite for cell therapy. J Mol Cell Cardiol. 2008, 45:514-22.
57. Rohde E, Malischnik C, Thaler D. Blood monocytes mimic endothelial progenitor cells. Stem Cells. 2006, 24:357-67.
58. Rohde E, Bartmann C, Schallmoser K. Immune cells mimic the morphology of endothelial progenitor colonies in vitro. Stem Cells. 2007, 25:1746-52.
59. Urbich C, Heeschen C, Aicher A. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation. 2003, 108:2511-6.
60. Romagnani P, Annunziato F, Liotta F. CD14+CD34low cells with stem cell phenotypic and functional features are the major source of circulating endothelial progenitors. Circ Res. 2005, 97:314-22.
61. Hur J, Yang HM, Yoon CH. Identification of a novel role of T cells in postnatal vasculogenesis: characterization of endothelial progenitor cell colonies. Circulation. 2007, 116:1671-82.